All Oncology News

Immunotherapy is emerging as a preferred second-line treatment option for patients with gynecologic cancers, including endometrial and cervical cancer. Checkpoint inhibitors may also be preferred to chemotherapy in the frontline or adjuvant settings based on improved efficacy.

The National Institute for Clinical Excellence has issued final guidance supporting the use of atezolizumab for patients with treatment-naïve, PD–L1–positive locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin.

The FDA has granted a priority review designation to a new drug application for lutetium-177-PSMA-617 for use in the treatment of patients with metastatic castration-resistant prostate cancer following androgen receptor pathway inhibition and taxane-based chemotherapy.

Cleveland Clinic has established a center focused on the diagnosis, care, and research of young-onset colorectal cancer.

Hussein A. Tawbi, MD, PhD, discusses the safety and efficacy achieved with relatlimab plus nivolumab in the RELATIVITY-047 trial and sheds light on the clinical significance of the data in the melanoma treatment paradigm.

Treatment of metastatic renal cell carcinoma continues to evolve as new regimens steadily receive FDA approval and are added to the armamentarium.

Kanwal P.S. Raghav, MBBS, MD, discussed nuances to treatment selection in mCRC, the significance of the phase 2 ReDOS trial with regorafenib, and how the paradigms for mCRC, HCC, and gastroesophageal cancers have expanded from areas of unmet need to ones with more robust armamentariums.

The FDA has granted a fast track designation to the first-in-class nucleotide analogue NUC-1031 for use as a potential therapeutic option in the frontline treatment of patients with advanced biliary tract cancer.

Health Canada has approved infigratinib for the treatment of adult patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma harboring a FGFR2 fusion or other rearrangement.

Sarah Cannon recently opened its newest drug development unit in collaboration with Florida Cancer Specialists & Research Institute and The University of Central Florida College of Medicine in Lake Nona, Flordia.

Cabozantinib demonstrated a sustained benefit in progression-free survival vs placebo in patients with previously treated, radioactive iodine–refractory differentiated thyroid cancer, regardless of prior exposure to sorafenib or lenvatinib.

Updated overall survival data from the phase 3 MONALEESA-3 trial demonstrated a sustained benefit with the addition of ribociclib to fulvestrant in patients with hormone receptor–positive, HER2-negative advanced breast cancer, and provide further evidence that this is a feasible approach for frontline therapy in this population.

Early-stage hormone receptor–positive, HER2-negative breast cancer is generally associated with a good prognosis; however, even with early intervention, some patients recur and have reduced survival.

The frontline triplet combination comprised of acalabrutinib, venetoclax, and obinutuzumab proved to be highly active and well tolerated when used in the treatment of patients with chronic lymphocytic leukemia.

The FDA has granted approval of a new indication for cetuximab plus encorafenib for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by a FDA-approved test, after prior therapy.

Germ cell tumors of the ovary are aggressive tumors derived from the primitive germ cells of the embryonic gonad and appear most often in young women or adolescent girls.

Sandra Duncan, RN, BSN, shares her experience with the CheckMate-73L trial of ipilimumab/nivolumab in non–small cell lung cancer, efforts made to overcome communication challenges, and the importance of nurse coordinators in the realm of clinical trials.

The investigational next-generation ROS1/NTRK inhibitor taletrectinib was found to elicit encouraging responses with an acceptable toxicity profile in patients with ROS1-positive non–small cell lung cancer, according to preliminary data from the phase 2 TRUST trial.

While overall cancer cases are declining, they are on the rise in older adolescents and young adults.

The FDA has granted priority review to a supplemental biologics license application for the use of cemiplimab-rwlc in the treatment of patients with recurrent or metastatic cervical cancer whose disease progressed on, or after, chemotherapy.

Rohit Jain, MD, MPH, discusses the nuances of treatment selection for patients with platinum-eligible vs -ineligible metastatic urothelial carcinoma, the current state of immunotherapy in this disease, and factors to consider during the decision-making process in RCC and mCRPC.

Despite early induced efficacy first- and second-generation tyrosine kinase inhibitors have limited efficacy for patients with chronic myeloid leukemia.

Hope S. Rugo, MD, discusses the final data from the phase 3 KEYNOTE-355 trial with pembrolizumab plus chemotherapy in patients with metastatic TNBC and the clinical impact on the treatment paradigm.

Jubilee Brown, MD, contextualizes updates in endometrial cancer and cervical cancer, frontline and second-line maintenance, and novel immune-oncology combination strategies in ovarian cancer.

The Japanese Ministry of Health, Labour, and Welfare has approved enfortumab vedotin for the treatment of patients with unresectable urothelial carcinoma that has progressed following chemotherapy.

The addition of pembrolizumab to best supportive care resulted in a statistically significant improvement in overall survival vs BSC alone in Asian patients with advanced hepatocellular carcinoma who previously received treatment with sorafenib, meeting the primary end point of the phase 3 KEYNOTE-394 trial.

The FDA has accepted the supplemental biologics license applications for nivolumab plus ipilimumab and nivolumab plus fluoropyrimidine- and platinum-containing chemotherapy in the frontline treatment of adult patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma.

One of the most influential and accomplished figures in the field of cancer immunotherapy has returned to his Western New York roots to take on leadership roles in both research and clinical care at Roswell Park Comprehensive Cancer Center.

Patients with relapsed/refractory multiple myeloma, particularly those who have failed a prior BCMA–targeted therapy, represent a population with an unmet need for effective treatment options. Investigators are hoping to help fill this void with the initiation of the phase 2 MagnetisMM-3 study.

Participating in a clinical trial is the most effective way to gain access to new and potentially better ways to treat cancer, yet we’ve seen a decrease in the number of African American and Hispanic patients participating in oncology trials in 2003 to 2016, compared with 1996 to 2002.